Antibodies and cancer therapy: versatile platforms for cancer immunotherapy

By L. Weiner, R. Surana, Shangzi Wang. Nature reviews. Immunology, 2010

1,230 citations recorded by the source corpus.

Antibodies are important therapeutic agents for cancer. Recently, it has become clear that antibodies possess several clinically relevant mechanisms of action. Many clinically useful antibodies can manipulate tumour-related signalling. In addition, antibodies exhibit various immunomodulatory properties and, by directly activating or inhibiting molecules of the immune system, antibodies can promote the induction of antitumour immune responses. These immunomodulatory properties can form the basis for new cancer treatment strategies.

Subfields: Immunology, Molecular Biology, Radiology, Nuclear Medicine and Imaging

View Paper: https://www.semanticscholar.org/paper/d2fde7ec27a2c6f8ff33aee6bdaa55b8c02f27f9

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

1. J. Wolchok
2. Lloyd J. Old
3. M. Kinder
4. P. Carter
5. Robert Schreiber

In Molecular Biology

1. A. Chan
2. P. Carter
3. J. Wolchok

In Radiology, Nuclear Medicine and Imaging

1. A. Chan
2. P. Carter

Citations in the corpus

• Strategies and challenges for the next generation of therapeutic antibodies (2010, background): “By contrast, diversification and validation of new targets in oncology is a challenging issu”
• A review of current nanoparticle and targeting moieties for the delivery of cancer therapeutics (2012, neutral): “The use of antibodies as targeting moieties has been extensively investigated over the past decade and has resulted in numerous available treatments (Table 1) (Adams and Weiner, 2005; Brannon-Peppas and Blanchette, 2004; Gu et al., 2007; Weber, 2007; Weiner et al., 2010).”
• Antibody therapy of cancer (2012, background): “Such therapeutics can function through mediating alterations in antigen or receptor function (such as agonist or antagonist functions), modulating the immune system (for example, changing Fc function and T cell activation) or delivering a specific drug that is conjugated to an antibody that target”
• Engineered Protease-resistant Antibodies with Selectable Cell-killing Functions* (2013, background): “Twenty-four-hour ADCP—Human PBMCs were isolated from leukopaks (Biologics Specialty) using Ficoll gradient centrifugation.”
• Therapeutic antibodies for autoimmunity and inflammation (2010, background): “jpg"/> Antibodies have rapidly become a clinically important drug class: more than 25 antibodies are approved for human therapy and more than 240 antibodies are currently in clinical development worldwide for a wide range of diseases, including autoimmunity and inflammation (the focus o”
• Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer (2012, neutral): “Squamous subtype 3 4 0 0 (0-60) NA 1 25 (0-81) 50 (1-99)”
• In vivo delivery of miRNAs for cancer therapy: Challenges and strategies (2014, background): “Immune escape due to ineffective FcγR binding and immunosuppressive microenvironment leads to the reduced therapeutic efficacy [9,10].”